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OBJECTIVEdTo assess the reversibility of the elevation of serum creatinine levels in patients
with diabetes after 5 years of continuous on-trial fenofibrate therapy.
RESEARCH DESIGN AND METHODSdAn on-drug/off-drug ancillary study to the
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial to investigate post-
trial changes in serum creatinine and cystatin C. Eligible participants were recruited into a
prospective, nested, three-group study based on retrospective on-trial serum creatinine levels:
fenofibrate case subjects (n = 321, $20% increase after 3 months of therapy); fenofibrate
control subjects (n = 175, #2% increase); and placebo control subjects (n = 565). Serum
creatinine and cystatin C were measured at trial end and 6–8 weeks after discontinuation of
trial therapy.
RESULTSdAt trial end, case subjects had the highest adjusted serum creatinine (6 SE) mg/dL
(1.11 6 0.02) and the lowest adjusted estimated glomerular filtration rate (eGFR) (6 SE)
mL/min/1.73 m2 (68.46 1.0) versus control subjects (1.016 0.02; 74.86 1.3) and placebo
subjects (0.986 0.01; 77.86 0.7). After 51 days off-drug, serum creatinine in case subjects was
still higher (0.976 0.02) and eGFR still lower (77.86 1.0) than control subjects (0.906 0.02;
81.8 6 1.3) but not different from placebo subjects (0.99 6 0.01; 76.6 6 0.7). Changes in
serum cystatin C recapitulated the serum creatinine changes.
CONCLUSIONSdParticipants with significant initial on-trial increases in serum creatinine
($20%) returned to the same level of renal function as participants receiving placebo while
participants who had #2% increase in serum creatinine had net preservation of renal function
compared with the same unselected placebo reference group. The fenofibrate-associated on-trial
increases in serum creatinine were reversible, and the reversal was complete after 51 days off-
drug. The similarity of the cystatin C results suggests that the mechanism of this change is not
specific for serum creatinine.
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Fenofibrate therapy is commonly pre-scribed for the clinical managementof elevated triglyceride levels in dia-
betic patients, but has been noted to cause
an elevation in serum creatinine concen-
trations. In several small studies, creatinine
levels increasedduring fenofibrate treatment
but returned to baseline after discontinua-
tion of therapy (1–4). In the Diabetes Ath-
erosclerosis Intervention Study (DAIS) of
the effects of fenofibrate on angiographically
demonstrated progression of coronary
artery disease in 418 individuals with
diabetes, serum creatinine rose 16% in
the fenofibrate-treated group and 0.2%
in the placebo group (5,6). In the
Fenofibrate Intervention and Event Lower-
ing in Diabetes (FIELD) Study of the effects
of fenofibrate on cardiovascular outcomes
in 9,795 individuals with diabetes, after the
prerandomization 6-week fenofibrate run-
in period, serum creatinine returned to
baseline levels after 4 months in those par-
ticipants randomized to receive the non-
fenofibrate placebo (7). In a post-FIELD
trial wash-out study in 7% of the partici-
pants (n = 661), serum creatinine fell by
16% (change in median 1.04–0.87 mg/dL)
in the fenofibrate group, but by 4% in the
placebo group (0.93–0.89 mg/dL) (7,8).
Although these data suggest that the
increase in creatinine is reversible, the ef-
fect has not been fully confirmed in large
studies or trials, and the mechanism un-
derlying the rapid elevation and subse-
quent decline on cessation of therapy is
not well understood. Given the appar-
ently rapid and complete reversibility in
most cases, it has been postulated that the
mechanism is an alteration of renal he-
modynamics. Increased creatinine pro-
duction has also been proposed (9) as has
decreased creatinine secretion in renal tu-
bules (10). Serum cystatin C, considered
to be a specific marker of glomerular fil-
tration rate (GFR), has been reported to
be unchanged (10) or increased (11,12)
during fenofibrate treatment. Similarly,
inulin clearance has been reported to be
unchanged in two smaller studies despite
increases in serum creatinine (10,13).
The Action to Control Cardiovascular
Risk in Diabetes (ACCORD) Lipid Trial
c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c
From the 1Department of PublicHealth Sciences,University ofVirginia School ofMedicine, Charlottesville, Virginia;
the 2Department of Biostatistical Sciences,Wake Forest University School ofMedicine,Winston-Salem,North
Carolina; the 3Department of Medicine, University of North Carolina School of Medicine, Chapel Hill,
North Carolina; the 4Department of Medicine,Wake Forest University School ofMedicine,Winston-Salem,
North Carolina; the 5Memphis VA Medical Center, Memphis, Tennessee; the 6G.V. (Sonny) Montgomery
VA Medical Center, Jackson, Mississippi; the 7Lang Center for Research and Education, Division of En-
docrinology, New York Hospital, Queens, Flushing, New York; the 8University of Washington, Northwest
Lipid Metabolism and Diabetes Research Laboratories, Seattle, Washington; the 9University of Iowa Di-
abetes Clinical Research, Iowa City, Iowa; the 10Health Partners Research Foundation, Minneapolis,
Minnesota; the 11NationalHeart, Lung, and Blood Institute,National Institutes ofHealth, Bethesda,Maryland;
and the 12Department of Medicine, Columbia University, New York, New York.
Corresponding author: Josyf C. Mychaleckyj, jcm6t@virginia.edu.
Received 27 September 2011 and accepted 20 January 2012.
DOI: 10.2337/dc11-1811. Clinical trial reg. no. NCT00000620, clinicaltrials.gov.
This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10
.2337/dc11-1811/-/DC1.
© 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for profit, and thework is not altered. See http://creativecommons.org/
licenses/by-nc-nd/3.0/ for details.
1008 DIABETES CARE, VOLUME 35, MAY 2012 care.diabetesjournals.org
C l i n i c a l C a r e / E d u c a t i o n / N u t r i t i o n / P s y c h o s o c i a l R e s e a r c h
O R I G I N A L A R T I C L E
offered a rare opportunity in a large cohort
to determine if the rise in creatinine seen
among some individuals upon starting
fenofibrate is reversible after prolonged
exposure to the drug.
RESEARCH DESIGN AND
METHODSdThe ACCORDTrial was a
double 2 3 2 factorial trial designed
to test the effect of 1) intensive glucose
control versus standard control, 2) inten-
sive blood pressure control versus stan-
dard control, and 3) lipid treatment
strategy that used fenofibrate plus a statin
compared with statin monotherapy on
the composite outcome of myocardial in-
farction, stroke, or cardiovascular death.
Details of the design of the ACCORD
Lipid Trial have already been published
(14–16). Briefly, 5,518 participants were
randomized to either fenofibrate or pla-
cebomedication. All participants received
simvastatin to assure good LDL control,
and participants were started on masked
medication (160 mg/day fenofibrate or
placebo) at the month 1 visit. All 77 par-
ticipating clinics obtained approval from
their local institutional review board prior
to participating. This ACCORD Renal An-
cillary Study was conducted among par-
ticipants of a subset of 40 clinics with a
total enrollment of 1,081 participants
(mean per clinic enrollment was 27, range
2–91). Participants read and signed an ad-
ditional informed consent before enroll-
ment in this study.
During the ACCORD Lipid Trial,
participants whose GFR fell below 50
mL/min/1.73 m2 for two consecutive vis-
its had their fenofibrate dose reduced
to 54 mg/day. Participants whose GFR
fell below 30 mL/min/1.73 m2 on two
consecutive visits had their fenofibrate
discontinued. To maintain masking, pla-
cebo arm participants who experienced
similar decreases in GFR were provided
with equivalent appearing, reduced dose
placebo tablets or had their placebo pills
discontinued. All GFR estimates for safety
reporting used the Modification of Diet in
Renal Disease method (17).
Study population and design
This study used a retrospectively defined,
nested, three group, on-drug/off-drug
study design. Eligible participants within
participating clinics were identified by
the Coordinating Center approximately 3
months prior to their ACCORDLipid Trial
close-out visit and reported to clinics
while maintaining masking to participant
randomization status. Fenofibrate arm
case subjects (“cases”) were defined as ac-
tive participants in the fenofibrate arm
who had experienced $20% increase in
serum creatinine from trial baseline to
month 4 and remained on study medica-
tion at close out (either full or reduced
dose). Since the study drug was started
1-month postrandomization, study month
4 was equivalent to 3 months of therapy.
Fenofibrate arm control subjects (“controls”)
were defined as active in the fenofibrate
armwho experienced#2% increase in cre-
atinine over the same period. Placebo arm
control subjects (“placebos”) were defined
as randomized to placebo but without re-
striction on their change in serum creati-
nine. Individuals with baseline renal
disease (creatinine .1.5 mg/dL) were ex-
cluded from ACCORD. All eligible cases
and controls that consented to participate
were enrolled in the study, while eligible
placebos were enrolled until maximum
enrollment was achieved.
The ACCORD Lipid Trial close-out
visit served as the baseline visit for the
ACCORD Renal Ancillary Study. A follow-
up visit for ancillary study participants was
held6–8weeks after the trial close-out visit,
referred to here as the “postclose-out” visit.
At both visits, a medication inventory was
obtained. At the trial close-out visit, all trial
participants were provided with a 3-month
supply of simvastatin, as well as their cur-
rent diabetes medications. No fenofibrate
was provided to any trial participant at
close out, and participants in the ancillary
study were given a letter asking their phy-
sician to refrain from starting open label
fenofibrate or other medications that could
affect serum creatinine or creatinine excre-
tion until after the postclose-out visit. This
protocol was approved by the institutional
review board at each clinic, at the Coordi-
nating Center, and at the ACCORD Renal
Study Center.
Renal measures
Serum creatinine was measured during the
ACCORD Lipid Trial at the baseline visit,
every 4 months throughout the trial, and
at the close-out visit. An additional blood
sample was drawn at the close-out and
postclose-out visits to assay serum creati-
nine and cystatin C. The same ACCORD
central laboratory performed all assays.
Serum creatinine was determined us-
ing the Roche Creatinine Plus enzymatic
assay with spectrometric analysis on a
Roche Double Modular P Analytics analyzer
(Roche Diagnostics, Indianapolis, IN). The
results are traceable to the isotope dilution
mass spectrometry reference method. The
assay sensitivitywas 0.03mg/dL, and intra-
assay coefficients of variation based on
analysis of low- and high-quality control
samples were 0.8% and 0.7%, respectively,
while interassay coefficients of variationwere
1.6% and 2.5%. The interassay precision is
consistently ,1.4% for the high-quality
and,2.2% for the low-quality control sam-
ples. Serum cystatin C concentrations were
determined using the Siemens Diagnostics
reagent on a Roche Hitachi P-Module an-
alyzer (Siemens Diagnostics, Deerfield, IL).
The interassay precision for the high- and
low-quality control samples was 2.5 and
2.6%, respectively. All serum samples were
analyzed for creatinine on the day of sample
receipt; cystatinCassayswereperformed in a
single batch from plasma previously stored
at 2808C. Estimated GFR (eGFR) in this
study was computed by the Chronic Kid-
ney Disease Epidemiology Collaboration
(CKD-Epi) method (18). Serum cystatin
C estimated glomerular filtration rate
(cGFR) was computed by the method of
Stevens et al. (19) (Eq. 2) with adjust-
ments for age, sex, and race.
Statistical analysis
Descriptive statistics were computed
overall and by each group. Pairwise dif-
ferences between groups were compared
using two-sample t tests for continuous
factors (with Satterthwaite correction for
unequal variances where appropriate) and
x2 tests for categorical factors. Between-
group comparisons of renal function
measures (serum creatinine, eGFR, serum
cystatin C, cystatin C-eGFR) were per-
formed using linear analysis of covariance
models. Each measure or outcome was
evaluated for normality and appropriately
transformed if warranted. All analyses were
performed using SAS version 9.2 software
(SAS Institute, Cary, NC).
Study power
The study power was estimated for the
change in creatinine levels after the trial
postclose-out visit based on two-group
t tests of differences in the log-transformed
serum creatinine. The estimates used
Satterthwaite approximation for unequal
variances at a Bonferroni-adjusted global
significance of 0.05. Based on projected
variability estimates prior to study close-
out, the power to detect a difference of 1.1
versus 1.0 mg/dL in serum creatinine
(i.e., a difference of 0.095 between log
means) was 91% for fenofibrate cases versus
fenofibrate controls; 99% for fenofibrate
cases versus placebo controls; and 94%
for fenofibrate controls versus placebo
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controls. Observed variability was less than
projected, yielding post hoc power esti-
mates of 99% for all three comparisons.
RESULTSdWe recruited 321 active
fenofibrate arm cases (30.2%), 175 active
fenofibrate arm controls (16.5%), and 565
active placebo controls (53.3%) plus 20
others (18 ineligible and 2 eligible but
missing required study data) for a total
ACCORD Renal Ancillary Study enroll-
ment of 1,081 participants. Forty-nine
individuals (4.6%) were lost to follow-up
between the trial close-out visit (the first
Renal Study on-drug visit) and postclose-
out (off-drug) visit. Two of the forty-nine
were deaths with causes not attributed to
this study. The clinical characteristics for
the three recruited study groups are listed
in Table 1. As expected, the change in se-
rum creatinine between the trial baseline
and month 4 visits was significantly differ-
ent between cases and controls with amean
(6 SD) increase of +0.316 0.16 mg/dL in
cases, decrease of20.056 0.08 mg/dL in
controls, and was also significantly differ-
ent between controls and placebos, with
placebos showing no change (0.00 6
0.13 mg/dL). Other differences between
the three groups included fewer control
participants in the intensive arm of the
ACCORD Glycemia Trial (37%) than cases
(55%) or placebos (49%); differences
among all three groups in the mean follow-
up time during the main trial from ran-
domization to close-out visit (5.06 1.0 vs.
5.66 1.6 vs. 5.26 1.2 years); more Asian
participants among controls (17%) than in
cases (10%) or placebo (10%); a lower tri-
glyceride level at trial close-out among
cases (1366 14mg/dL) than either controls
(1606 227 mg/dL) or placebos (1636 93
mg/dL); greater use of insulin by cases at trial
close-out (62%) than among controls
(49%); and more cases (58%) with a creat-
inine.1.0 mg/dL at close-out than among
either controls (38%) or placebos (36%).
There were no significant differences in
Table 1dClinical characteristics of the nested fenofibrate case, fenofibrate control, and placebo control study groups























Serum creatinine (Lipid Trial
month 4 visitdtrial baseline)
(mg/dL), mean change (SD) 321 0.31 (0.16) 175 20.05 (0.08) 564 0.00 (0.13) ,0.0001 ,0.0001 ,0.0001
Randomized to intensive
glycemia control arm 321 55 (177) 175 37 (64) 565 49 (276) ,0.001 0.07 0.004
Follow-up time, randomization
to trial close-out visit,
mean years (SD) 321 5.0 (1.0) 175 5.6 (1.6) 565 5.2 (1.2) ,0.0001 0.05 0.001
Age, mean (SD)* 321 67.2 (6.2) 175 66.9 (6.5) 565 67.3 (7.1) 0.6 0.7 0.5
Female sex 321 30 (97) 175 40 (70) 565 35 (197) 0.02 0.2 0.2
Total nonwhite race 321 35 (111) 175 46 (80) 565 38 (213) 0.02 0.4 0.06
African American 321 13 (43) 175 15 (26) 565 16 (92) 0.7 0.3 0.7
Asian 321 10 (33) 175 17 (29) 565 10 (55) 0.04 0.8 0.01
Hispanic 321 8 (25) 175 12 (21) 565 9 (52) 0.1 0.5 0.3
Duration of diabetes,
mean years (SD)* 318 16.1 (7.4) 173 15.2 (7.0) 559 15.4 (7.3) 0.2 0.2 0.8
HbA1c, mean (SD)* 320 7.6 (1.3) 174 7.6 (1.2) 561 7.6 (1.2) 0.8 0.6 0.5
HDL cholesterol (mg/dL),
mean (SD)* 321 41.5 (10.3) 174 42.6 (11.1) 561 41.5 (9.1) 0.3 1.0 0.2
Triglycerides (mg/dL),
mean (SD)* 321 136 (74) 174 160 (227) 561 163 (93) 0.2 ,0.001 0.9
Systolic BP (mm Hg),
mean (SD)* 313 129 (16) 170 131 (15) 558 130 (16) 0.1 0.3 0.3
Diastolic BP (mmHg),
mean (SD)* 313 68 (10) 170 70 (10) 558 70 (10) 0.07 0.09 0.5
History of CVD* 321 39 (124) 175 39 (68) 565 41 (233) 1.0 0.4 0.6
History of
microalbuminuria* 319 43 (136) 175 49 (85) 563 45 (253) 0.2 0.5 0.4
History of
macroalbuminuria* 319 8 (26) 175 11 (19) 563 8 (42) 0.3 0.7 0.2
Use of insulin* 320 62 (198) 175 49 (86) 565 58 (326) 0.006 0.2 0.05
Use of ACEI/ARB* 321 67 (215) 175 67 (117) 565 68 (384) 1.0 0.8 0.8
Use of TZD* 320 33 (104) 175 30 (53) 565 27 (154) 0.6 0.1 0.4
Serum creatinine .1.0* 321 58 (186) 175 38 (66) 565 36 (205) ,0.001 ,0.001 0.7
Data are % (n) unless otherwise stated. *Characteristics are measures at the ACCORD Lipid Trial close-out visit. BP, blood pressure; CVD, cardiovascular disease;
ACEI/ARB, ACE inhibitor/angiotensin receptor blocker; TZD, thiazolidinedione.
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mean time interval between close-out
and postclose-out visits for the three
groups (Table 2). Creatinine levels in ca-
ses remained higher than controls at
study close-out after a mean of 5.2 years
of follow-up, although the creatinine
levels in cases declined from the month
4 visit to close-out visit, while that of the
controls and placebos increased, nar-
rowing the difference in the means be-
tween the groups.
Table 2 shows the adjusted mean cre-
atinine and eGFR for the three groups at
four time points during the trial and the
postclose-out visit. The same data are
plotted in Figs. 1A and 2A. The mean val-
ues in Table 2 were adjusted for glycemia
treatment arm assignment, age, diabetes
duration, sex, nonwhite race, insulin use,
and systolic and diastolic blood pressure;
the change in values were additionally ad-
justed for the time interval between visits
(trial baseline to month 4, or trial close-
out to postclose-out visit). All subsequent
results in the main text refer to these ad-
justed values (unadjusted values are in-
cluded for comparison in Supplementary
Table 1). The mean serum creatinine levels
in the three study groups were not signifi-
cantly different at baseline ormonth 4 from
the other participants in the main lipid trial
who would have satisfied the retrospective
percent change in serum creatinine inclu-
sion criterion and were thus representative
of the entire eligible ACCORD Lipid Trial
cohort at month 4.
In the retrospectively defined nested
groups, the mean (6 SE) serum creatinine
at the month 4 visit was greater in cases
(1.16 6 0.01 mg/dL) than in controls
(0.90 6 0.01 mg/dL) or placebos (0.90 6
0.01 mg/dL). No difference was seen be-
tween controls and placebos (P = 0.9). At
the trial close-out visit after a mean trial
follow-up period of 5.2 years (range
5.0–5.6 years in the three groups), serum
creatinine was still greater in cases than
controls or placebos (1.11 6 0.02 mg/dL
versus 1.016 0.02mg/dL and 0.986 0.01
mg/dL, respectively) although the difference
in the means of the three groups decreased.
Table 2dTime course of primary renal outcomes for the 3 study groups in ACCORD Lipid Trial and Renal Ancillary Study





















(end of trial) and postclose-out
(follow-up), days 309 50.3 (0.6) 164 51.2 (0.9) 539 50.9 (0.4) 0.4 0.4 0.8
Adjusted serum creatinine
(mg/dL)
Trial baseline 321 0.85 (0.01) 175 0.94 (0.01) 564 0.90 (0.01) ,0.0001 ,0.0001 0.005
Trial month 4 visit 321 1.16 (0.01) 175 0.90 (0.02) 565 0.90 (0.01) ,0.0001 ,0.0001 0.9
Trial close-out visit 321 1.11 (0.02) 175 1.01 (0.02) 565 0.98 (0.01) ,0.0001 ,0.0001 0.2
Trial postclose-out visit† 308 0.97 (0.02) 164 0.90 (0.02) 536 0.99 (0.01) 0.008 0.3 0.0002
Mean change, trial
baseline-to-4 month 321 0.31 (0.01) 175 20.05 (0.01) 564 0.0 (0.01) ,0.0001 ,0.0001 0.0002
Mean change, trial close-out
to postclose-out visit 308 20.13 (0.01) 164 20.09 (0.01) 536 0.02 (0.01) 0.002 ,0.0001 ,0.0001
Adjusted eGFR (mL/min/1.73 m2)
Trial baseline 321 90.0 (0.8) 175 82.0 (1.1) 564 85.9 (0.6) ,0.0001 ,0.0001 0.002
Trial month 4 visit 321 66.9 (0.9) 175 86.0 (1.2) 565 86.1 (0.6) ,0.0001 ,0.0001 0.9
Trial close-out visit 321 68.4 (1.0) 175 74.8 (1.3) 565 77.8 (0.7) 0.0002 ,0.0001 0.05
Trial postclose-out visit† 308 77.7 (1.0) 164 81.8 (1.4) 536 76.6 (0.7) 0.02 0.4 0.001
Mean change, trial baseline-
to-4 month visit 321 223.1 (0.5) 175 4.0 (0.7) 564 0.2 (0.4) ,0.0001 ,0.0001 ,0.0001
Mean change, trial close-out
to postclose-out visit 308 9.0 (0.5) 164 6.3 (0.7) 536 21.3 (0.4) 0.002 ,0.0001 ,0.0001
Adjusted cystatin C (mg/dL)
Trial close-out visit 315 1.03 (0.02) 171 0.95 (0.02) 537 0.95 (0.01) 0.002 ,0.0001 0.5
Trial postclose-out visit† 299 0.96 (0.02) 158 0.88 (0.02) 520 0.97 (0.01) 0.003 0.9 ,0.0001
Mean change, trial close-out to
postclose-out visit 293 20.07 (0.01) 155 20.06 (0.01) 497 0.02 (0.01) 0.4 ,0.0001 ,0.0001
Adjusted cGFR (mL/min/1.73 m2)
Trial close-out visit 315 76.0 (1.3) 171 84.7 (1.8) 537 85.6 (1.0) 0.0001 ,0.0001 0.6
Trial postclose-out visit† 299 83.1 (1.4) 158 91.4 (1.9) 520 83.1 (1.0) 0.0003 0.9 ,0.0001
Mean change, trial close-out to
postclose-out visit 293 7.3 (0.7) 155 6.6 (0.9) 497 22.0 (0.5) 0.6 ,0.0001 ,0.0001
Participants were off masked study medication at the visit. Means were adjusted for glycemia treatment arm assignment, age, diabetes duration, sex, nonwhite race,
insulin use, systolic blood pressure, and diastolic blood pressure. Means of differences were also adjusted for individual time interval between visits. †The postclose-
out visit was the visit for ancillary study participants only that occurred 6–8 weeks post Lipid Trial close-out visit.
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At the postclose-out visit after dis-
continuation of the fenofibrate study drug
for 51 days, the mean creatinine had de-
creased markedly in both cases (average
decrease20.1360.01mg/dL) and controls
(average decrease20.096 0.01 mg/dL),
but showed a slight increase in placebos
(average increase +0.02 6 0.01 mg/dL).
The absolute magnitude of reduction in
serum creatinine was significantly greater
in cases than in controls (P = 0.002), and
also different in both cases and controls
compared with a slight rise in placebos
(P, 0.0001 for both comparisons). After
discontinuation of the study drug for 6–8
weeks, cases had a mean serum creatinine
of 0.12 mg/dL above trial baseline mean,
while controls were 0.04 mg/dL below
their baseline mean, although identical
to their mean value at trial month 4. Sim-
ilar between-group trends were observed
in eGFR. At postclose-out, the mean eGFR
of cases was 1.1 mL/min/1.73 m2 greater
than placebos but not significant (P = 0.4),
while controls were 5.2 mL/min/1.73 m2
greater than placebos (P, 0.0001). These
results did not change substantially af-
ter removing participants who stopped
taking nonfenofibrate, renal function–
altering medications between close-out
and postclose-out visits (further details
in the Supplementary Data online). The
Supplementary Data also includes analy-
ses that suggest that the reduction in se-
rum creatinine was essentially complete
after 51 days.
Changes in adjusted serum cystatin C
levels between close-out and postclose-out
visits recapitulated those of serum creati-
nine, Table 2, and Figs. 1B and 2B. In cases,
cystatin C dropped from a mean (6 SE)
of 1.03 6 0.02 to 0.96 6 0.02 mg/dL
and was not significantly different from
placebos at postclose-out (P = 0.9). Con-
trols likewise dropped from 0.956 0.02
to 0.886 0.02 mg/dL. The mean change
in cases and controls was not signifi-
cantly different (P = 0.4). Trends in ad-
justed cGFR were similar to eGFR with
mean cGFR in controls at postclose-out
(91.4 6 1.9 mL/min/1.73 m2) greater
than either cases (83.1 6 1.4) or placebos
(83.1 6 1.0), which were not significantly
different (P = 0.9). The mean recovery of
cGFR was also greater in cases and con-
trols on drug cessation compared with
placebos.
CONCLUSIONSdWe investigated
the potential reversibility of the rapid se-
rum creatinine increase observed on start-
ing fenofibrate therapy. The fenofibrate
cases (participants who experienced a 20%
ormore increase in serum creatinine after 3
months of fenofibrate; 47.4% of all partic-
ipants randomized to fenofibrate in the
ACCORDLipidTrial) had amean serumcre-
atinine decrease on cessation of fenofibrate
to a value that was no different than the
mean creatinine of the placebo reference
group, suggesting no residual loss of GFR
after 5 years of therapy. This reversal of
serum creatinine elevation was complete
after 51 days off therapy. By contrast, for
the control subgroup of fenofibrate par-
ticipants (participants who experienced
,2% change in creatinine; 24.6% of all
participants randomized to fenofibrate),
the mean serum creatinine was lower
than the placebo reference group after
Figure 1dTime course values of adjusted serum creatinine and cystatin C by ACCORD Re-
nal Study Group. A: The changes in serum creatinine in units of mg/dL. B: Changes in cystatin
C in units of mg/dL. The horizontal trial time point axis is not shown to scale. The study group
trends are shown as: black circles, fenofibrate cases; red triangles, fenofibrate controls; blue
crosses, placebo controls. Base, baseline visit; M4, month 4 visit; Close, close-out visit; Post,
postclose-out visit. (A high-quality color representation of this figure is available in the online
issue.)
Figure 2dTime course values of adjusted eGFR and cGFR by ACCORD Renal Study Group. A:
The changes in eGFR in units of mL/min/1.73m2. B: Changes in cGFR in units of mL/min/1.73 m2.
The horizontal trial time point axis is not shown to scale. The study group trends are shown as:
black circles, fenofibrate cases; red triangles, fenofibrate controls; blue crosses, placebo controls.
Base, baseline visit; M4, month 4 visit; Close, close-out visit; Post, postclose-out visit. (A high-
quality color representation of this figure is available in the online issue.)
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51 days off therapy, suggesting a net pres-
ervation of GFR and renal function. The
serum cystatin C results showed similar
trends.
Fenofibrate was also found to have a
protective effect on the albuminuria levels
inACCORDLipid Trial participants. Fewer
participants randomized to fenofibrate
progressed to frank microalbuminuria or
proteinuria postrandomization than place-
bos (16). This result is consistent with the
reducedprogression found in theDAIS and
FIELD Trials (5,7), and the greater reduc-
tion in mean urinary albumin/creatinine
ratio in the fenofibrate arm compared
with placebo over 5 years of follow-up in
FIELD (7). The ACCORD Lipid Trial albu-
minuria results will be reported in detail
elsewhere.
Previous studies support our key find-
ing about the reversibility of serum creat-
inine levels postfenofibrate therapy. Early
comparative studies in patients who had
undergone renal transplant and were on
fenofibrate therapy demonstrated a re-
versible increase in creatinine if no chronic
renal failure was present at baseline (1,2).
A limitation of these early reports is that
they were all retrospective case studies in a
limited number of patients with pre-existing
renal disease or transplant. The FIELDTrial
reported results from a large study of re-
versibility of renal function in patients
with diabetes on fenofibrate therapy. After
a 6-week prerandomization run-in period of
all FIELD study participants on fenofibrate
therapy, mean levels of serum creatinine in-
creased, but returned to baseline in those
subjects randomized to placebo within 4
months of cessation of therapy. Further-
more, a posttrial fenofibrate wash-out sub-
study at the conclusion of the 5-year trial
demonstrated an acute decline in creatinine
values during the wash-out period of 52
days resulting in a net protective effect of
fenofibrate (7,8). Similar to ACCORD, the
FIELD Trial examined a broad population
of type 2 diabetic participants who had nor-
mal renal function at study entry.
Our results suggest the presence of
two distinct clinical effects of fenofibrate
therapy. The first is the previously studied
rise in serum creatinine levels shortly after
starting therapy. Based on the ACCORD
results, this can be expected to occur in
47% of type 2 diabetic patients with a
similar cardiovascular and renal function
profile to the participants in the ACCORD
Lipid Trial. This rise appears to be wholly
reversible after 5 years of therapy. The
second effect is a preservation of GFR in
patients who experience little or no rise in
serum creatinine immediately after initi-
ating therapy, which is expected in about
25% of patients with a similar profile to
ACCORD Lipid. A similar protective effect
on GFR was also seen in fenofibrate
participants more generally at the con-
clusion of the FIELD Trial (7). Whether
this preservation is maintained or whether
it reduces the long-term macro- or mi-
crovascular disease risk after the initial
5 years of therapy is unknown. The
ACCORDION (ACCORD Follow-Up)
Study, which is currently underway,
will help to answer the second question.
ACCORDION is a posttrial, prospective,
observational study of 8,000 ACCORD
participants over 3.5 years to elucidate the
long-term effects of the ACCORD treat-
ment strategy and will include additional
measurements of serum creatinine, uri-
nary creatinine, and albumin.
The underlying mechanism for the
increase in creatinine is not understood.
Potential mechanisms include increased
muscular production of creatinine, de-
creased secretion from renal tubules,
and a change in the glomerular filtration
through altered hemodynamics. Hottelart
et al. (9) postulated that increased serum
creatinine levels result from increased cre-
atinine production. The investigators
performed a crossover study of 15 pa-
tients with renal insufficiency (average
creatinine clearance 69 mL/min) that
had experienced at least a 10% increase
in serum creatinine with fenofibrate ther-
apy. Renal function was assessed follow-
ing discontinuation of fenofibrate therapy
and following rechallenge. Serum creati-
nine increased with fenofibrate therapy,
but indices of both GFR (creatinine clear-
ance, inulin clearance) and renal bloodflow
(p-aminohippuric acid clearance) were un-
affected. A similar, small, cross-over study
in healthy individuals found that while cre-
atinine clearance was reduced by fenofi-
brate, neither GFR as measured by inulin
clearance nor the rate of creatinine secretion
changed (10). Similar changes have been
seen in some but not all drugs in this class.
Fifty-five patients treated with ciprofibrate
showed similar results but no significant
change was observed in 15 patients taking
gemfibrozil. Similar results were observed
byWestphal et al. (11) in a cross-over study
of 22 men with hypertriglyceridemia and
normal renal function randomized to either
micronized fenofibrate 200 mg/day or
gemfibrozil 900 mg/day.
The cystatin C results in the ACCORD
Renal Study are consistent with the FIELD
Helsinki substudy, which showed that an
increase in cystatin C levels accompanied
the initial increase in serum creatinine with
fenofibrate (12). The results suggest that
the physiological mechanism for the rapid
increase in serum creatinine on initiation
of fenofibrate therapy (and the reversion
on cessation) is not specific for creatinine
and rule out increased creatinine pro-
duction or secretion as a plausible mech-
anism. However, more work needs to be
done to confirm and elaborate these
findings.
An unexpected benefit of this design
was that it highlighted the differences in
changes in serum creatinine and cystatin
C in major subgroups of trial participants
once these subgroups ceased on-trial
therapy. These different responses would
typically not have been identified in an
on-drug/off-drug study that recruited
without regard to the magnitude of the ini-
tial serum creatinine increase and analyzed
the mean of the single active fenofibrate
group, such as in the FIELDTrial (7,8). The
selection of the case and control subgroups
in this study also had its limitations, how-
ever. Interpretation of the serum marker
trends in these groups during the trial
and posttrial is complicated by the effect
of single point-in-time selection of the ex-
tremes of percent change of serum creati-
nine and statistical regression to the mean.
This study did not analyze the changes in
the 28% of patients with intermediate re-
sponse in percent serum creatinine after
3 months (2–20% change in serum creati-
nine). Furthermore, the choice of 20% and
2% as thresholds for change in serum cre-
atinine was arbitrary, albeit that they are
clinically meaningful levels of change/no
change. Finally, participants who had sig-
nificant worsening of renal function and
required discontinuation of study medica-
tion are not included in this substudy. De-
spite these limitations, these results can
assist clinical decision making for type 2
diabetic patients with comparable cardio-
vascular and renal profile according to their
percent serum creatinine change in re-
sponse to initiation of fenofibrate therapy.
This study found that about 50% of
ACCORD type 2 diabetic participants ex-
perienced an increase of 20% or more in
serum creatinine levels immediately upon
starting fenofibrate therapy, while approx-
imately 25% had no increase. For those
participantswith a creatinine increase of 20%
or more, the increase was reversible and not
associatedwith an adverse effectdcompared
with placebodon renal function over 5
years. Those with no increase in creatinine
upon starting fenofibrate appeared to have
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less renal function loss compared with pla-
cebo over 5 years of therapy. More work
needs to be done to test these findings over
longer durations of therapy, to determine
if this apparent renal protection is also
seen among the low HDL/high triglycer-
ide subgroup that had apparent cardio-
vascular benefit in the main ACCORD
Lipid Study, and to determine the duration
of the apparent renal protective effects.
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